Table 1 Pathological and clinical data of the arrayed prostate cancers
No. of patients (%) | ||
|---|---|---|
Study cohort on TMA (n = 12,427) | Biochemical relapse among categories | |
Follow-up (mo) | ||
n | 11,665 (93.9%) | 2769 (23.7%) |
Mean | 62.9 | − |
Median | 50.0 | − |
Age (y) | ||
≤50 | 334 (2.7%) | 81 (24.3%) |
51–59 | 3061 (24.8%) | 705 (23%) |
60–69 | 7188 (58.2%) | 1610 (22.4%) |
≥70 | 1761 (14.3%) | 370 (21%) |
Pretreatment PSA (ng/ml) | ||
<4 | 1585 (12.9%) | 242 (15.3%) |
4–10 | 7480 (60.9%) | 1355 (18.1%) |
10–20 | 2412 (19.6%) | 737 (30.6%) |
>20 | 812 (6.6%) | 397 (48.9%) |
pT stage (AJCC 2002) | ||
pT2 | 8187 (66.2%) | 1095 (13.4%) |
pT3a | 2660 (21.5%) | 817 (30.7%) |
pT3b | 1465 (11.8%) | 796 (54.3%) |
pT4 | 63 (0.5%) | 51 (81%) |
Gleason grade | ||
≤3 + 3 | 2848 (22.9%) | 234 (8.2%) |
3 + 4 | 6679 (53.8%) | 1240 (18.6%) |
3 + 4 Tert.5 | 433 (3.5%) | 115 (26.6%) |
4 + 3 | 1210 (9.7%) | 576 (47.6%) |
4 + 3 Tert.5 | 646 (5.2%) | 317 (49.1%) |
≥4 + 4 | 596 (4.8%) | 348 (58.4%) |
pN stage | ||
pN0 | 6970 (91%) | 1636 (23.5%) |
pN+ | 693 (9%) | 393 (56.7%) |
Surgical margin | ||
Negative | 9990 (81.9%) | 1848 (18.5%) |
Positive | 2211 (18.1%) | 853 (38.6%) |